
Imaging and biomarkers are driving earlier, more individualized GA treatment

Imaging and biomarkers are driving earlier, more individualized GA treatment

When no retina podcast was available, Jayanth Sridhar, MD, created one—and learned lessons about branding, bandwidth, and mentorship along the way.

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

AI revolutionizes ophthalmology with enhanced diagnostics, personalized treatments, and improved surgical precision, offering better patient outcomes and efficient clinical trials.

This approach helps distinguish diseases associated with macular atrophy.

The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.